From routine checkup to recovery: Raegan’s neuroblastoma journey
A 15-month well visit led to unexpected tests, a neuroblastoma diagnosis and a cross-hospital treatment plan that moved a family from shock to remission and ongoing surveillance.
A 15-month well visit led to unexpected tests, a neuroblastoma diagnosis and a cross-hospital treatment plan that moved a family from shock to remission and ongoing surveillance.
A routine low hemoglobin result at a 15-month visit prompted further testing that revealed a large adrenal mass diagnosed as neuroblastoma.
Care combined local chemotherapy at Akron Children’s with specialized surgery and a bone marrow transplant at Cincinnati Children’s through a coordinated clinical trial.
Family-centered communication, named nurses and a child life specialist were critical supports during treatment and recovery.
# How a routine well visit uncovered neuroblastoma
At Raegan Glendon's 15-month well visit, a routine hemoglobin check came back lower than expected. The family and pediatrician initially considered iron deficiency. When a repeat test matched the result, additional labs were ordered and the pediatrician called the Glendons the same day to go to Akron Children's.
During the exam, Raegan winced when the doctor pressed her abdomen. An overnight ultrasound identified a large mass. Subsequent testing confirmed neuroblastoma, a childhood cancer that most often develops in the adrenal gland. In Raegan's case, tumor testing found a genetic marker associated with high-risk disease.
# Immediate shift to aggressive treatment
Because of Raegan's age and tumor location, the oncology team led by Dr. Hannah Elkus recommended an aggressive plan. Treatment began right away, and the family's daily routine shifted to hospital stays, appointments and therapies.
Akron Children's enrolled Raegan in a clinical trial that allowed her to receive chemotherapy locally and travel to Cincinnati Children's for specialized surgery and a bone marrow transplant. The family described the handoffs between the two hospitals as seamless, with clear communication among physicians and care teams.
# What the treatment involved
Raegan completed her final inpatient immunotherapy stay just before Christmas 2025. In February 2026 she rang a bell to mark the end of active treatment.
# Recovery and follow-up
# The people who mattered
Kelly, Raegan's mother, singled out specific clinicians and support staff by name. She credited Dr. Elkus for direct, unbiased discussions about options. Several nurses—Maddie, Brooke, Alicia, Lizzie, Jackie, Kenna and Erin—helped make lengthy hospital stays more tolerable. The family also noted the value of Renee, a child life specialist, who provided emotional and practical support beyond medical care.
# What the family learned
Kelly says Raegan taught the family about resiliency and how to find joy amid hardship. At age 3, Raegan is active at home in Green, Ohio. She celebrated a recent birthday with a mermaid-themed party alongside her 5-year-old sister, Gianna.
# Practical points for readers

Chris Carosielli would be the first to tell you that having her 19-year-old daughter, Ava, diagnosed with cancer just a few months after high school graduation wasn’t on her bingo card for 2026. Ava was preparing to begin college at Henderson State University in Arkansas. The four-year state qualifier for North Canton

At 3 years old, Teagan Riley could not understand why the people who loved her most kept taking her to a place filled with needles, medicine and frightening procedures.

Hearing your child has cancer is the worst news a parent can possibly get. For one family, that nightmare became a reality when their 3-year-old son was diagnosed with hepatoblastoma — a condition the National Cancer Institute identifies as the most common type of childhood liver cancer in kids under three. The primary

At nine years old, Joey has been cancer-free for three and a half years.

At nine years old, Joey has been cancer-free for three and a half years.
There are patients you remember for their diagnosis. And then there are patients you remember for who they were. He was the second kind. Years ago, during my time in oncology clinical research, I met a patient with multiple myeloma. At the time, I was working as a supervisor in a hematology-oncology clinical research u
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.